NAHDI MEDICAL COMPANY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 132.6 SAR | +0.76% |
|
-0.60% | -3.07% |
| May. 08 | Nahdi Medical Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 08 | Nahdi Medical Logs Lower Q1 Net Profit; Revenue Rises | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 21,736 | 17,810 | 17,108 | - | - |
| Enterprise Value (EV) 1 | 21,828 | 18,075 | 17,516 | 17,284 | 17,141 |
| P/E ratio | 24.5 x | 19.9 x | 20.8 x | 18.2 x | 17.1 x |
| Yield | - | 4.01% | 3.8% | 4.38% | 4.89% |
| Capitalization / Revenue | 2.52 x | 2.04 x | 1.88 x | 1.79 x | 1.68 x |
| EV / Revenue | 2.53 x | 2.07 x | 1.93 x | 1.81 x | 1.69 x |
| EV / EBITDA | 13.6 x | 11.5 x | 11.2 x | 10.2 x | 9.6 x |
| EV / FCF | - | 18.4 x | 19.5 x | 19 x | 16.3 x |
| FCF Yield | - | 5.45% | 5.13% | 5.27% | 6.14% |
| Price to Book | 9.69 x | 7.92 x | 6.67 x | 6.23 x | 5.93 x |
| Nbr of stocks (in thousands) | 130,000 | 130,000 | 130,000 | - | - |
| Reference price 2 | 167.2 | 137.0 | 131.6 | 131.6 | 131.6 |
| Announcement Date | 3/20/23 | 3/17/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 8,616 | 8,714 | 9,094 | 9,574 | 10,167 |
| EBITDA 1 | - | 1,599 | 1,578 | 1,558 | 1,693 | 1,785 |
| EBIT 1 | - | 1,003 | 961 | 885.8 | 1,000 | 1,068 |
| Operating Margin | - | 11.64% | 11.03% | 9.74% | 10.45% | 10.51% |
| Earnings before Tax (EBT) 1 | - | - | 944.2 | 951.5 | 1,045 | 1,120 |
| Net income 1 | 812.5 | 887.8 | 892.6 | 825.3 | 939.9 | 1,004 |
| Net margin | - | 10.3% | 10.24% | 9.07% | 9.82% | 9.87% |
| EPS 2 | 6.250 | 6.830 | 6.870 | 6.336 | 7.219 | 7.704 |
| Free Cash Flow 1 | - | - | 984.2 | 899 | 910.7 | 1,052 |
| FCF margin | - | - | 11.3% | 9.89% | 9.51% | 10.35% |
| FCF Conversion (EBITDA) | - | - | 62.37% | 57.71% | 53.8% | 58.92% |
| FCF Conversion (Net income) | - | - | 110.26% | 108.93% | 96.88% | 104.8% |
| Dividend per Share 2 | - | - | 5.500 | 5.005 | 5.770 | 6.436 |
| Announcement Date | 4/3/22 | 3/20/23 | 3/17/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 2,239 | 2,159 | 2,138 | 2,105 | - | 2,163 | 2,214 | 2,258 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | 305.8 | 278.5 | 153.9 | 263.2 | - | 229.8 | 215.1 | 231.6 |
| Operating Margin | - | 13.66% | 12.9% | 7.2% | 12.51% | - | 10.62% | 9.71% | 10.26% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income 1 | 237.5 | 268.5 | 253.8 | 128 | - | 265 | - | - | 232.9 |
| Net margin | - | 11.99% | 11.76% | 5.99% | - | - | - | - | 10.32% |
| EPS | 1.830 | 2.070 | - | 0.9900 | - | 2.040 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/23/22 | 8/11/22 | 11/3/22 | 3/20/23 | 5/11/23 | 8/3/23 | 11/5/23 | 3/17/24 | 5/8/24 |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 91.8 | 265 | 408 | 176 | 33.4 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.0574 x | 0.168 x | 0.2618 x | 0.1042 x | 0.0187 x |
| Free Cash Flow 1 | - | - | 984 | 899 | 911 | 1,052 |
| ROE (net income / shareholders' equity) | - | 46.2% | 37.9% | 32.6% | 35.8% | 35.7% |
| ROA (Net income/ Total Assets) | - | 19.2% | 17.3% | 15.5% | 16.1% | 16.2% |
| Assets 1 | - | 4,616 | 5,158 | 5,338 | 5,840 | 6,187 |
| Book Value Per Share 2 | - | 17.30 | 17.30 | 19.70 | 21.10 | 22.20 |
| Cash Flow per Share 2 | - | 12.80 | 10.50 | 10.10 | 10.40 | 9.070 |
| Capex 1 | - | 275 | 385 | 446 | 365 | 373 |
| Capex / Sales | - | 3.19% | 4.41% | 4.91% | 3.81% | 3.66% |
| Announcement Date | 4/3/22 | 3/20/23 | 3/17/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
131.6
SAR
Average target price
153
SAR
Spread / Average Target
+16.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.07% | 4.56B | |
| -38.30% | 13.9B | |
| -32.35% | 10.68B | |
| +11.56% | 6.24B | |
| -11.61% | 5.96B | |
| +73.30% | 4.72B | |
| -6.67% | 3.87B | |
| -19.00% | 3.17B | |
| -13.44% | 2.86B | |
| -12.31% | 2.53B |
- Stock Market
- Equities
- 4164 Stock
- Financials Nahdi Medical Company
